Subcutaneous Infliximab in Refractory Crohn’s Disease Patients: A Possible Biobetter?

BACKGROUND: A subcutaneous formulation of infliximab (IFX-SC) approved to treat patients with inflammatory bowel disease may offer improved efficacy versus intravenous infliximab. METHODS: Patients with refractory Crohn’s disease (CD, n = 32) previously treated unsuccessfully with at least 2 biologi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cerna, Karin, Duricova, Dana, Lukas, Martin, Kolar, Martin, Machkova, Nadezda, Hruba, Veronika, Mitrova, Katarina, Kubickova, Kristyna, Kostrejova, Marta, Jirsa, Jakub, Kastylova, Kristyna, Peterka, Stepan, Vojtechova, Gabriela, Lukas, Milan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
360 Hot Topics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640858/
https://www.ncbi.nlm.nih.gov/pubmed/38028954
http://dx.doi.org/10.1093/crocol/otad040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640858/
https://www.ncbi.nlm.nih.gov/pubmed/38028954
http://dx.doi.org/10.1093/crocol/otad040

Ejemplares similares